Cardano Risk Management B.V. Sells 14,358 Shares of Amgen Inc. $AMGN

Key Points

• Cardano Risk Management B.V. reduced its Amgen stake by 5.2%, selling 14,358 shares and retaining 260,359 shares valued at approximately $94.3 million. Institutional investors own 76.5% of Amgen’s stock.
• Amgen exceeded second-quarter expectations, reporting adjusted EPS of $6.29 and revenue of $10.05 billion, up 9.5% year over year. The company raised its 2026 earnings guidance to $22.30–$23.50 per share, though it discontinued obesity candidate AMG 513.
• Analyst sentiment remains mixed, with a consensus rating of Hold and an average price target of $370.07, despite several firms raising targets as high as $450. Amgen also declared a quarterly dividend of $2.52, equivalent to a 2.5% annual yield.

Cardano Risk Management B.V. reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 260,359 shares of the medical research company's stock after selling 14,358 shares during the period. Cardano Risk Management B.V.'s holdings in Amgen were worth $94,281,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Anfield Capital Management LLC boosted its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC raised its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC lifted its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after acquiring an additional 63 shares during the last quarter. Manning & Napier Advisors LLC lifted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in shares of Amgen during the fourth quarter worth approximately $34,000. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on AMGN. Wells Fargo & Company upped their target price on Amgen from $390.00 to $400.00 and gave the company an "equal weight" rating in a research report on Wednesday. BMO Capital Markets lifted their price target on Amgen from $400.00 to $450.00 and gave the stock an "outperform" rating in a report on Wednesday. Morgan Stanley boosted their price target on Amgen from $333.00 to $351.00 and gave the company an "equal weight" rating in a research note on Wednesday. Daiwa Securities Group decreased their price objective on Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada increased their price objective on Amgen from $370.00 to $400.00 and gave the stock an "outperform" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $370.07.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.85% of the stock is owned by corporate insiders.

Amgen Stock Up 1.5%

Shares of AMGN opened at $410.95 on Friday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $418.40. The firm's 50 day moving average is $362.77 and its 200-day moving average is $356.24. The stock has a market capitalization of $222.17 billion, a PE ratio of 25.54, a P/E/G ratio of 3.83 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts forecast that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen's payout ratio is currently 62.65%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source